BPN.F - Medibio Limited

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Medibio Limited

8696 Eagle Creek Circle
Savage, MN 55378
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Melanie Jaye Leydin C.A., B.Bus, CAJoint Company Sec. & DirectorN/AN/A1973
Dr. Adam William Darkins MB, ChB., MPHM, M.D., FRCSConsultantN/AN/AN/A
Mr. David B. KaysenChairman, CEO & MDN/AN/A1950
Ms. Peggy MorganCorp. ControllerN/AN/AN/A
Ms. Stephanie OttensInvestor Relations DirectorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Medibio Limited, a medical health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. It is involved in the research, development, and commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. Medibio Limited has a research agreement with the Department of Biomedical Sciences of Humanitas University for the development of mental health software products. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was founded in 1998 and is headquartered in Savage, Minnesota.

Corporate Governance

Medibio Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.